Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown remarkable clinical activity in patients with chronic myelogenous leukaemia (CML). However, this drug does not ...

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-1018 Crossref ...

One patient harbored F317L+K247R amino-acid exchanges together and was considered as an F317L alone for statistical analysis, as the ABL mutation K247R is considered as a polymorphism. 16, 17 The ...

PATIENTS AND METHODS: Direct sequencing analysis of BCR‑ABL gene was performed in 92 patients treated with IM for more than 3 months. The mean time of IM treatment was 18 months. At the time of the ...